Akrevia launches with $30M in Series A financing
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.
Akrevia Therapeutics
The company, with ARIAD and Intellia veterans at the helm, aims to develop CTLA4-targeting monoclonal antibody that mitigates the immune toxicity of Bristol's Yervoy.